Related Experiment Video
Updated: Oct 25, 2025
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
17.1K
Histone H3.3 G34-mutant Diffuse Gliomas in Adults
Leiming Wang1, Liwei Shao1, Hainan Li2
1Departments of Pathology.
The American Journal of Surgical Pathology
|August 5, 2021
Summary
Adults with H3.3 G34-mutant gliomas are diagnosed younger and have distinct molecular features compared to IDH/H3 wild-type gliomas. These H3.3 G34-mutant gliomas exhibit a poorer prognosis, highlighting the need for targeted therapies.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Genetics
Background:
- H3.3 G34-mutant diffuse gliomas in adults are not well-characterized.
- Understanding their distinct features is crucial for diagnosis and treatment.
Purpose of the Study:
- To describe the clinical and pathological characteristics of adult H3.3 G34-mutant diffuse gliomas.
- To compare their molecular profiles and prognosis against IDH/H3 wild-type adult diffuse gliomas.
Main Methods:
- Retrospective review of 30 adult H3.3 G34-mutant diffuse gliomas.
- Molecular profiling via next-generation sequencing in 29 patients.
- Comparison with 82 IDH/H3 wild-type adult diffuse glioma patients.
Main Results:
- H3.3 G34-mutant gliomas occurred at a significantly younger age (24 vs. 57 years).
- Frequent findings included Olig-2 loss, TP53, ATRX, PDGFRA mutations, and MGMT methylation.
- H3.3 G34-mutant gliomas showed a dismal prognosis (14 vs. 22 months survival).
Conclusions:
- Adult H3.3 G34-mutant gliomas possess unique pathological and molecular signatures.
- TP53 mutation and extent of resection independently impact prognosis.
- These findings underscore the clinical significance of H3.3 G34R/V mutation detection and advocate for dedicated therapeutic strategies for this rare glioma subtype.
